Genelux Corporation (GNLX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.T ...

Immunovant, Inc. (IMVT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investo ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

BOULDER, Colo., Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to develop and commercialize a kit-based version of Foresight's CLARITY™ assay, with the goal of enabling global in vitro diagnostic (IVD) and companion diagnostic (CDx) applications in lymphoma and other hematological malignancies.Th ...

Core Insights - Cat Footwear, a division of Wolverine World Wide, Inc., is celebrating Caterpillar Inc.'s 100th anniversary by launching a limited-edition boot collection that honors significant achievements in engineering [1][2] - The collection includes three boots, each representing a monumental feat: the Golden Gate Bridge, the Apollo 11 Moon Landing, and the Channel Tunnel System [1][2][6] Company Overview - Cat Footwear is the official footwear licensee of Caterpillar and has been expanding the Cat brand globally since 1994, now offering products in nearly 140 countries [4] - The brand is known for its rugged and durable footwear, paralleling the strength of Caterpillar's machinery [4] Caterpillar Inc. Overview - Caterpillar Inc. reported sales and revenues of $64.8 billion in 2024, making it the leading manufacturer in construction and mining equipment, as well as engines and turbines [5] - The company operates across three primary segments: Construction Industries, Resource Industries, and Energy & Transportation, while also providing financing through its Financial Products segment [5] Product Features - The Golden Gate Bridge Boot features a structural cage and cable system design, with gold hardware [6] - The Apollo 11 Boot is lightweight with a stacked sole, inspired by lunar exploration gear [6] - The Channel Tunnel Boot includes a functioning headlight and sole lights, mimicking trains in a tunnel [6]

Group 1 - The article emphasizes the distinction between "income investors" who focus on current yield and those who prioritize total return, suggesting that the latter can find mispriced or undervalued securities [1] - It highlights the belief that the next decade will favor fixed income investments, regardless of the investor's approach, whether conservative or aggressive [1] - The company promotes its Conservative Income Portfolio, which targets preferred stocks and bonds with high safety margins, indicating a strategic focus on fixed income securities [1] Group 2 - The article mentions opportunities in undervalued fixed income securities, bond ladders, and high-yield cash parking, appealing to investors looking for attractive investment options [2] - It also offers access to an options portfolio as a bonus, suggesting additional investment strategies available to clients [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Semler Scientific Inc. and its officers or directors [1] Company Summary - Semler Scientific Inc. filed its annual report for 2024 on February 28, 2025, indicating a risk of a civil complaint from the U.S. Department of Justice related to the False Claims Act [3] - The company received an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3] - Settlement discussions with the DOJ in February 2025 were unsuccessful [3] Market Reaction - Following the news of the investigation and potential legal issues, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4]

Financial analyst by day and a seasoned investor by passion, I've been involved in the world of investing for over 15 years and honed my skills in analyzing lucrative opportunities within the market.I specialize in uncovering high quality dividend stocks and other assets that offer potential for long term-growth that pack a serious punch for bill-paying potential. I use myself as an example that with a solid base of classic dividend growth stocks, sprinkling in some Business Development Companies, REITs, an ...

Core Viewpoint - Ollie's Bargain Outlet is set to release its first-quarter earnings results, with expectations of a slight decline in earnings per share and an increase in revenue compared to the previous year [1]. Financial Performance - The company is projected to report quarterly earnings at 71 cents per share, down from 73 cents per share in the same period last year [1]. - Quarterly revenue is expected to reach $565.75 million, an increase from $508.82 million a year earlier [1]. - In the fourth quarter, adjusted earnings per share were reported at $1.19, aligning with analyst consensus, while quarterly sales were $667.1 million, which was a 2.8% year-over-year increase but fell short of the consensus estimate of $674.5 million [2]. Analyst Ratings and Price Targets - Keybanc analyst Bradley Thomas maintained an Overweight rating and increased the price target from $125 to $135 [9]. - JP Morgan analyst Matthew Boss also maintained an Overweight rating, raising the price target from $135 to $137 [9]. - Piper Sandler analyst Peter Keith maintained an Overweight rating but reduced the price target from $126 to $124 [9]. - UBS analyst Mark Carden maintained a Neutral rating and raised the price target from $117 to $123 [9]. - Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating and increased the price target from $108 to $118 [9].

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Savara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 27, 2025, Sava ...